Literature DB >> 15906130

Novel therapeutics in colorectal cancer.

Robert R McWilliams1, Charles Erlichman.   

Abstract

Colorectal cancer is an excellent tumor model for evaluating novel therapeutic strategies. Development of a mechanistic understanding of how this cancer develops, spreads, and grows allows a tailored approach to all stages of treatment: prevention, adjuvant treatment, and therapy of advanced disease. We focus on therapy in the advanced disease setting, although progress in this area could lend itself to treatment of early or premalignant disease. In the last 20 years, information has been generated about the intracellular pathways of tumor formation, invasion, and metastasis. As a result, specific molecular processes have been targeted for therapeutic intervention, including cell surface growth factor receptors, proliferation signaling, cell cycling, apo-ptosis, angiogenesis, and matrix metalloproteinases. We review the scientific rationale for recently developed novel therapeutics in colorectal cancer, and the results of clinical trials to date. We also suggest appropriate clinical settings for specific targets and outline future directions of research.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15906130     DOI: 10.1007/s10350-005-0026-8

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  6 in total

1.  The effect of bevacizumab on colon anastomotic healing in rats.

Authors:  Efstathios T Pavlidis; Konstantinos D Ballas; Nikolaos G Symeonidis; Kyriakos Psarras; Georgios Koliakos; Kokona Kouzi-Koliakos; Konstantina Topouridou; Savas F Rafailidis; Theodoros E Pavlidis; Georgios N Marakis; Athanasios K Sakantamis
Journal:  Int J Colorectal Dis       Date:  2010-08-06       Impact factor: 2.571

Review 2.  Panitumumab: in the treatment of metastatic colorectal cancer.

Authors:  Sheridan M Hoy; Antona J Wagstaff
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 3.  Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.

Authors:  Efstathios T Pavlidis; Theodoros E Pavlidis
Journal:  World J Gastroenterol       Date:  2013-08-21       Impact factor: 5.742

4.  Colorectal Cancer Therapy Using a Pediococcus pentosaceus SL4 Drug Delivery System Secreting Lactic Acid Bacteria-Derived Protein p8.

Authors:  Byung Chull An; Yongku Ryu; Yeo-Sang Yoon; Oksik Choi; Ho Jin Park; Tai Yeub Kim; Song-In Kim; Bong-Kyu Kim; Myung Jun Chung
Journal:  Mol Cells       Date:  2019-11-30       Impact factor: 5.034

5.  Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas.

Authors:  Peng Xu; Yang Zhao; Kang Liu; Shuai Lin; Xinghan Liu; Meng Wang; Pengtao Yang; Tian Tian; Yu-Yao Zhu; Zhijun Dai
Journal:  Cancer Manag Res       Date:  2017-12-12       Impact factor: 3.989

6.  Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition.

Authors:  Yu-Wei Lin; Emmanuel Naveen Raj; Wei-Siang Liao; Johnson Lin; Kuang-Kai Liu; Ting-Hua Chen; Hsiao-Chun Cheng; Chi-Ching Wang; Lily Yi Li; Chinpiao Chen; Jui-I Chao
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.